Leslie A Khawli

Summary

Affiliation: Genentech Inc
Country: USA

Publications

  1. ncbi Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model
    Cinthia V Pastuskovas
    Genentech Research and Early Development, South San Francisco, California, USA
    Mol Cancer Ther 11:752-62. 2012
  2. ncbi Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats
    Leslie A Khawli
    Department of Pharmacokinetic and Pharmacodynamic Sciences, Genentech, Inc, South San Francisco, CA, USA
    MAbs 2:613-24. 2010
  3. ncbi Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow
    C Andrew Boswell
    Department of Pharmacokinetic and Pharmacodynamic Sciences, Genentech Inc, South San Francisco, California, United States of America
    PLoS ONE 6:e17874. 2011
  4. ncbi Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice
    Daniela Bumbaca
    Department of Pharmacokinetic and Pharmacodynamic Sciences, Genentech Research and Early Development, South San Francisco, CA, USA
    Br J Pharmacol 166:368-77. 2012

Collaborators

  • Alavattam Sreedhara
  • Ruediger E Port
  • Cynthia Quan
  • Daniela Bumbaca
  • C Andrew Boswell
  • Paul J Fielder
  • Frank Peter Theil
  • Eduardo E Mundo
  • Cinthia V Pastuskovas
  • Sheila Ulufatu
  • Shannon L Stainton
  • Nicholas Majidy
  • Tapan K Nayak
  • Nicholas Lewin-Koh
  • Anil Bagri
  • Gary Cain
  • Sheila Bheddah
  • Peter Nauka
  • Suzanna Clark
  • Hong Xiang
  • Mark Sliwkowski
  • Kathryn Parsons-Reponte
  • Jason Ho
  • Jay Tibbitts
  • Simon P Williams
  • Marjie van Hoy
  • Sarajane Ross
  • Katherine R Kozak
  • Josefa Dela Cruz Chuh
  • Eric Cheng
  • Ben Quan Shen
  • Michelle G Schweiger
  • Gregory Z Ferl

Detail Information

Publications4

  1. ncbi Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model
    Cinthia V Pastuskovas
    Genentech Research and Early Development, South San Francisco, California, USA
    Mol Cancer Ther 11:752-62. 2012
    ..These findings may ultimately help inform dosing strategies to achieve improved clinical outcomes...
  2. ncbi Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats
    Leslie A Khawli
    Department of Pharmacokinetic and Pharmacodynamic Sciences, Genentech, Inc, South San Francisco, CA, USA
    MAbs 2:613-24. 2010
    ....
  3. ncbi Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow
    C Andrew Boswell
    Department of Pharmacokinetic and Pharmacodynamic Sciences, Genentech Inc, South San Francisco, California, United States of America
    PLoS ONE 6:e17874. 2011
    ..In particular, the growing interest in preclinical evaluation of anti-angiogenic agents alone or in combination with other drugs requires a complete understanding of the associated physiological consequences...
  4. ncbi Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice
    Daniela Bumbaca
    Department of Pharmacokinetic and Pharmacodynamic Sciences, Genentech Research and Early Development, South San Francisco, CA, USA
    Br J Pharmacol 166:368-77. 2012
    ..The objective of this study was to assess MNRP1685A biodistribution in tumour-bearing mice to understand the relationships between dose, non-tumour tissue uptake and tumour uptake...